By Fineline Cube CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its self-developed Class 1 innovative drug, Ammuxetine Enteric-Coated Tablets (HA1406), successfully met its primary efficacy endpoint in patients with major depressive disorder (MDD) / depression. The novel agent demonstrated statistically significant differences and clear clinical benefits with a favorable safety profile, positioning it as a promising candidate for first-line therapy in depression management.
Trial Overview
| Item | Detail |
|---|---|
| Sponsor | CSPC Pharmaceutical Group Limited (HKG: 1093) |
| Drug Candidate | Ammuxetine Enteric-Coated Tablets (HA1406) |
| Classification | Class 1 innovative drug (China NMPA) |
| Drug Class | Novel, potent, and selective serotonin and norepinephrine reuptake inhibitor (SNRI) |
| Trial Phase | Phase III |
| Indication | Major depressive disorder (MDD) / depression |
| Primary Endpoint | Met with statistical significance |
| Safety Profile | Favorable |
| Therapeutic Positioning | Potential first-line therapy |
Drug Profile & Mechanism of Action
- Molecule: Ammuxetine (HA1406)
- Formulation: Enteric-coated tablets (optimized delivery)
- Mechanism: Dual inhibition of serotonin and norepinephrine reuptake
- Pharmacological Advantage: Enhanced selectivity profile compared to existing SNRIs
- Innovation Status: Self-developed Class 1 innovative drug representing significant domestic pharmaceutical advancement
Clinical Evidence Highlights
| Parameter | Result | Significance |
|---|---|---|
| Primary Efficacy Endpoint | Met | Statistically significant difference vs. control |
| Clinical Benefit | Clear and meaningful | Meets regulatory and clinical practice thresholds |
| Safety Profile | Favorable | Supports chronic dosing in depression management |
| Therapeutic Index | Optimized | Balances efficacy with tolerability for first-line use |
The trial results demonstrate that Ammuxetine achieves the critical balance required for first-line antidepressant therapy: robust efficacy combined with manageable side effects suitable for long-term treatment.
Market Impact & Strategic Implications
- Depression Treatment Landscape: Addresses significant unmet need in China’s estimated 95 million adults affected by depression, with only 8% receiving adequate treatment
- First-Line Opportunity: Potential to compete with established global SNRIs including venlafaxine, duloxetine, and desvenlafaxine, which collectively generate $3+ billion annually in major markets
- China Innovation Leadership: As a Class 1 innovative drug, Ammuxetine represents CSPC’s commitment to developing truly novel therapeutics rather than me-too compounds
- Commercial Advantages:
- Domestic manufacturing ensures supply chain security
- Potential pricing advantages over imported alternatives
- Alignment with China’s healthcare cost-containment policies
- Global Expansion Potential: Successful development could support international regulatory filings, particularly in emerging markets seeking affordable, effective depression treatments
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for Ammuxetine. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market acceptance, and additional data requirements for marketing approval.-Fineline Info & Tech